Rhumbline Advisers Adc Therapeutics Sa Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Rhumbline Advisers holds 102,608 shares of ADCT stock, worth $301,667. This represents 0.0% of its overall portfolio holdings.
Number of Shares
102,608
Previous 111,629
8.08%
Holding current value
$301,667
Previous $157,000
74.52%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ADCT
# of Institutions
88Shares Held
67.5MCall Options Held
53.7KPut Options Held
75.8K-
Redmile Group, LLC San Francisco, CA15.7MShares$46.1 Million5.11% of portfolio
-
Prosight Management, LP Dallas, TX10.5MShares$30.8 Million7.6% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct7.76MShares$22.8 Million0.05% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.91MShares$17.4 Million0.57% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$10.5 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $228M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...